Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

• Главные авторы: Sui Wai Ling (Автор), Erik de Blois (Автор), Eline Hooijman (Автор), Astrid van der Veldt (Автор), Tessa Brabander (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2022-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited. Therefore, beta and alpha radionuclide therapy (RNT) have emerged as novel treatment options for patients...